scholarly journals Efficacy and maintenance of rituximab treatment in non‐infectious scleritis

2021 ◽  
Author(s):  
Daphne P. C. Vergouwen ◽  
Jan A. M. Laar ◽  
Josianne C. Ten Berge ◽  
Wishal D. Ramdas ◽  
Aniki Rothova
Keyword(s):  
Infectious Scleritis

Infectious Scleritis after Subtenon Triamcinolone Acetonide Injection

2011 ◽  
Vol 19 (4) ◽  
pp. 284-285 ◽  
Author(s):  
Hamid Gharaee ◽  
Mohammad Khalife ◽  
Setareh Sagheb Hossein Poor ◽  
Mojtaba Abrishami
Keyword(s):  
Triamcinolone Acetonide ◽  
Infectious Scleritis

Infectious Scleritis after Retinal Surgery

2008 ◽  
Vol 145 (4) ◽  
pp. 695-699 ◽  
Author(s):  
Ryan M. Rich ◽  
William E. Smiddy ◽  
Janet L. Davis
Keyword(s):  
Retinal Surgery ◽  
Infectious Scleritis

Management of Infectious Scleritis After Pterygium Excision

Cornea ◽  
2000 ◽  
Vol 19 (1) ◽  
pp. 34-39 ◽  
Author(s):  
Fu-Chin Huang ◽  
Shen-Perng Huang ◽  
Sung-Huei Tseng
Keyword(s):  
Pterygium Excision ◽  
Infectious Scleritis

scholarly journals Pseudomonas Scleritis following Pterygium Excision

2017 ◽  
Vol 8 (2) ◽  
pp. 401-405 ◽  
Author(s):  
Winai Chaidaroon ◽  
Sumet Supalaset
Keyword(s):  
Early Recognition ◽  
Antimicrobial Treatment ◽  
Surgical Debridement ◽  
Eye Drops ◽  
Chiang Mai ◽  
Laboratory Findings ◽  
Department Of Ophthalmology ◽  
History Of ◽  
Pterygium Excision ◽  
Infectious Scleritis

Purpose: The aim of this case report was to describe a patient who presented with Pseudomonas scleritis after pterygium excision. The study was conducted at the Department of Ophthalmology, Faculty of Medicine, Chiang Mai University in Chiang Mai, Thailand. Methods: The record of a patient who was diagnosed as Pseudomonas scleritis after pterygium excision was retrospectively reviewed for history, clinical characteristics, laboratory findings, treatments, and outcomes. Results: We described a 66-year-old male patient with a history of pterygium excision in his right eye 10 years ago, he presented with infectious scleritis. Scleral thinning, tissue necrosis, and overlying calcified plaque were found. The culture of scleral scraping revealed Pseudomonas aeruginosa. Topical fortified amikacin (20 mg/mL) and intravenous ceftazidime were started. Urgent surgical debridement of scleral infiltrates and irrigation of necrotic sclera and surrounding conjunctiva with fortified amikacin (20 mg/mL) were performed. After 2 weeks of treatment, scleral thinning and inflammation decreased, and the best-corrected visual acuity improved from 6/24 to 6/9. Fortified amikacin eye drops (20 mg/mL) were continued until the fourth week, with no scleral thinning seen. Conclusions: P. aeruginosa is a virulent organism that causes infectious scleritis complicated by melting and necrotizing of the sclera. This report emphasized that early recognition, intensive antimicrobial treatment, and surgical debridement can prevent morbidity related to this Pseudomonas infection.

scholarly journals Rituximab for non-infectious Uveitis and Scleritis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Caleb C. Ng ◽  
Aileen Sy ◽  
Emmett T. Cunningham
Keyword(s):  
Granulomatosis With Polyangiitis ◽  
Therapeutic Response ◽  
Immunosuppressive Agents ◽  
Review Of Literature ◽  
Autoimmune Retinopathy ◽  
Infectious Uveitis ◽  
Infusion Reactions ◽  
Third Line Therapy ◽  
Infectious Scleritis ◽  
Third Line

Abstract Purpose To provide a comprehensive review of rituximab use for the treatment of non-infectious uveitis and scleritis. Methods Review of literature through December 2020. Results Individual data was available for 229 patients with refractory non-infectious uveitis (n = 108) or scleritis (n = 121) who received treatment with rituximab (RTX). Rituximab was generally utilized as third-line or later treatment (uveitis: 67/90, 74.4%; scleritis: 90/96, 93.8%) at a mean of 33.5 months following the diagnosis of uveitis (range = 0 to 168.0 months; median = 24.0 months) and 39.4 months after diagnosis of scleritis (range = 1.0 to 168.0 months; median = 21.0 months). Patients with non-infectious uveitis and scleritis either received prior treatment with corticosteroids only (uveitis: 18/90, 20%; scleritis: 4/94, 4.3%), or with one (uveitis: 19/90, 21.1%; scleritis: 30/94, 31.9%), two (uveitis: 11/90, 12.2%; scleritis 27/94, 28.7%), or three or more (uveitis: 37/90, 41.1%; scleritis: 31/94, 33.0%) corticosteroid-sparing immunosuppressive agents with or without corticosteroids before initiation of RTX treatment. The rheumatologic protocol (two infusions of 1 gram of RTX separated by 14 days) was utilized most frequently (uveitis: 45/87, 51.7%; scleritis: 87/114, 76.3%), followed by the Foster protocol (eight weekly infusions of 375 mg/m2 RTX; uveitis: 18/87, 20.7%; scleritis: 10/114, 8.8%), and the oncologic protocol (four weekly infusions of 375 mg/m2 RTX; uveitis: 5/87, 5.7%; scleritis: 6/114, 5.3%). Various other off-label regimens were used infrequently (uveitis: 19/87, 21.8%; scleritis 11/114, 9.6%). Rituximab treatments resulted in a positive therapeutic response for the majority of patients with non-infectious uveitis (81/97, 83.5%). Commonly treated uveitic diagnoses included non-paraneoplastic autoimmune retinopathy (30/107, 28.0%), juvenile idiopathic arthritis (21/107, 19.6%), Vogt-Koyanagi-Harada disease (12/107, 11.2%), and Behçet disease (11/107, 10.3%). Cases of non-infectious scleritis were most commonly attributed to granulomatosis with polyangiitis (75/121, 62.0%) and rheumatoid arthritis (15/121, 12.4%), and showed an even greater rate of positive therapeutic response (112/120, 93.3%) following RTX treatment. No side effects were reported in 76.3% (74/97) of uveitis and 85.5% (71/83) scleritis cases. Of those cases associated with RTX-induced adverse events, the most common were infusion reactions of various severity (11/35, 31.4%). Conclusions Overall, RTX appeared to be both effective and well-tolerated as second or third-line therapy for patients with non-infectious uveitis and scleritis.

Infectious Scleritis in Taiwan—A 10-Year Review in a Tertiary-Care Hospital

Cornea ◽  
2014 ◽  
Vol 33 (8) ◽  
pp. 838-843 ◽  
Author(s):  
Yeen-Fey Ho ◽  
Lung-Kun Yeh ◽  
Hsin-Yuan Tan ◽  
Hung-Chi Chen ◽  
Yeong-Fong Chen ◽  
...  
Keyword(s):  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Care Hospital ◽  
Infectious Scleritis
Sign in / Sign up

Export Citation Format

Share Document